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While many HIV-positive pregnant women already receive potent combinations of antiretroviral agents, a bolus dose of i.v. zidovudine administered over one hour, followed by a continuous zidovudine i.v. infusion during labor, and oral zidovudine for the newborn remain core components of the most recent recommendations for vertical transmission prophylaxis. 2 Oxytocin is a hormone peptide that stimulates uterine contractions. It is used to induce or augment an estimated 30% of all newborn deliveries in the United States. 3 Therefore, in HIV-infected pregnant women, there is a high likelihood that i.v. zidovudine and oxytocin will be coadministered. Currently, there are no data describing whether these two medications are physically or chemically compatible. Oxytocin dosing is usually continuously adjusted to achieve a certain physiological effect, whereas zidovudine is given in a fixed weight-based dose. If incompatibility would cause a loss of drug activity, the oxytocin dosage would likely be increased until the desired effect is reached, but zidovudine loss may not be immediately clinically apparent and could lead to the serious consequence of diminished prophylactic activity. The objective of this study was to determine the stability of zidovudine and the visual and pH compatibility of an i.v. formulation of zidovudine mixed with an i.v. formulation of oxytocin. The study was designed to simulate the mixing of these agents that would occur when one drug is infused via a primary i.v. line and the other drug is piggybacked into the same i.v. line via a Y-site port.
Methods. Sample preparation. Hospital stock of 10-mg/mL zidovudine injection solution a and 10-units/mL, oxytocin injection solution b were separately compounded in 5% dextrose injection solution.
c Two concentrations of zidovudine, 4 and 2 mg/mL, were prepared in 5% dextrose injection solution. Oxytocin in 5% dextrose injection was compounded to a final concentration of 10 milliunits/mL. 4, 5 The drug solutions were prepared in plastic containers on the day of the study and transported to our laboratory. All experimental solutions were stored at approximately 20 °C during transportation and in the laboratory. i The column was maintained at 35 °C. The mobile phase consisted of 85% 25 mM sodium phosphate with a pH of 4.62 and 15% acetonitrile (by volume). The flow rate was 1.0 mL/min and the injection volume was 10 µL. The detection wavelength was set at 266 nm. The retention time for zidovudine was 7.6 minutes. The selectivity of the assay for zidovudine in the presence of oxytocin was investigated by inspecting the chromatograph 7.6 minutes after injecting a 10-milliunits/mL sample of oxytocin into the column.
To ensure that zidovudine degradation products did not interfere with the assay, forced zidovudine degradation was conducted with sodium hydroxide in a heated (95 °C) water bath. Zidovudine 0.2 mg/mL was mixed with 0.1 N sodium hydroxide (1 mL:1 mL) as reported by previous investigators, and additional aliquots of 10 N sodium hydroxide were added as necessary. 5 After heating, solutions were neutralized with hydrochloric acid and assayed for zidovudine and degradation products.
For assay validation, six zidovu- NOTES dine standard concentrations j were prepared over the range of 0.5-100 µg/mL. Standard curves were fit with the equation y = mx + b and weighted with the reciprocal of the concentration. Three concentrations of quality-control (QC) samples were prepared at 0.5, 1.0, and 2.0 mg/mL. All QC and test solutions were diluted 100-fold with 0.9% sodium chloride for injection and mixed in a vortex mixer immediately before the assay. Three validation runs were performed on separate days with five replicates of QC solutions at each concentration and two standard curves, one at the beginning and one at the end of each run.
Zidovudine stability. The zidovudine 4-and 2-mg/mL solutions were assayed before mixing with oxytocin to establish time zero concentrations. All the zidovudine concentrations after mixing with oxytocin were compared with the concentration at time 0. A loss of zidovudine concentration exceeding 10% in the presence of oxytocin was chosen a priori to indicate significant degradation. 5 A 50-mL aliquot of each zidovudine solution was transferred to a 125-mL clear glass bottle, and an equal volume of oxytocin solution was then added to this zidovudine solution; the contents of the bottle were mixed well. Zidovudine concentration was measured immediately and at one, three, and six hours after mixing. All samples were assayed in triplicate. At all time points, the admixtures were also assayed for pH values and visually inspected for evidence of gas emission, precipitation, or color change.
Results. The interassay and intraassay precision (QC coefficient of variation) was less than 1.5% and accuracy was 99.8-100.8% of the nominal QC concentration for all QC levels ( Table 1 ). The standards demonstrated coefficients of variation of <0.62%. The selectivity of the assay for zidovudine in the presence of oxytocin was confirmed by a clean chromatograph in the retention window for zidovudine after the addition of oxytocin.
The forced degradation studies demonstrated a 64% loss of zidovudine in the basic solution, with all degradation peaks eluting before zidovudine at <4, 5.38, and 6.51 minutes (Figure 1) . Because 100% degradation was not observed, the same solution was injected in the HPLC system with a mobile phase of 80% 25 mM sodium phosphate pH 4.62 and 20% acetonitrile (by volume) to further investigate assay selectivity. Zidovudine was retained at 5.5 minutes and exhibited 64% degradation. Using both mobile phases, the 64% decline in zidovudine in the chromatograph corresponded with a 64% increase in the degradation peaks in the chromatograph. There was negligible widening of the zidovudine peak in the degraded zidovudine sample versus the nondegraded zidovudine sample. These experiments were considered evidence that the assay was stability indicating.
The mean ± S.D. zidovudine concentrations in the 4-and 2-mg/mL solutions at time zero were 4.01 ± 0.013 and 2.00 ± 0.011 mg/mL. There was no deviation of ≥2.5% from these initial concentrations at any time after mixing with oxytocin compared with concentrations at time zero (Table 2 ). The pH was 4.80-4.83 during the study. There was no evidence of gas emission, precipitate formation, or color change.
Discussion. In this Y-site simulated compatibility study, zidovudine in 5% dextrose injection was stable in the presence of oxytocin in 5% dextrose injection for up to six hours, and no physical incompatibilities were observed. The largest deviation in zidovudine concentration during the study was a decrease of 2.5%, well below the predefined stability threshold of 10%. This 2.5% decrease occurred in the zidovudine-oxytocin mixture with the 4-mg/mL zidovudine solution. The lower concentrations observed for the 4-mg/mL zidovudine experiments were probably artifacts. The aliquot of the 4-mg/mL solution was transferred to a container that had been rinsed with water and not dried, which likely caused some dilution of the concentration. After this was recognized, the 2-mg/ mL solution was transferred to a container that had been rinsed with water and the same 2-mg/mL zidovudine solution. Thus, the largest decrease over the course of the study for the 2-mg/mL zidovudine-oxytocin mixture was -0.5%.
A stability-indicating assay for zidovudine was used in this study. Our success in forcibly degrading zidovudine was limited compared with what was reported in another study, 5 which found that zidovudine would not degrade with hydrochloric acid but was effectively degraded by mixing 0.1 N sodium hydroxide with 0.2-mg/L zidovudine (1:1) and heating the mixture at 100 °C for 24 hours using a similar HPLC method used in our study. We replicated these methods and found virtually no zidovudine degradation under very similar conditions. A small difference was that our water bath incubator only reached a temperature of approximately 95 °C. To achieve the reported 64% degradation, we changed the above conditions by adding an additional 0.1 mL of 10 N a Mean of five replicates. b After 100-fold dilution. Zidovudine with oxytocin sodium hydroxide and continued heating the sample over eight days, not including a weekend in that time frame. Other methods of chemical degradation, such as hydrogen peroxide or light, were not tried. We demonstrated that there were no peaks beneath the remaining zidovudine signal by using different chromatographic mobile phases that changed the column retention of zidovudine by approximately 27% (from 7.6 to 5.5 minutes). We found that both the zidovudine and degradation signal intensities remained the same with two conditions. In addition, the zidovudine peak width and the degradation peak signals in relation to the loss of zidovudine peak signal were the same. Table 2 . 
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